The association between MYC and disease aggressiveness was documented in other B‐cell malignancies, including the progression of follicular lymphoma, mucosa‐associated lymphoid tissue lymphoma, and chronic lymphocytic leukemia (CLL) from their indolent forms to more aggressive, treatment‐refractory phases [93, 94]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.